[ad_1]
The study of real-world evidence LIGHTNING-PM demonstrates that insulin glargine 300 U / mL significantly reduced the rate of severe hypoglycemia in 25% of cases compared with the previous year. insulin degludec in people starting treatment of type 2 diabetes with second-generation basal insulin.
The LIGHTNING-PM study shows that insulin glargine 300 U / mL significantly reduced the rate of severe hypoglycemia in 25% of cases compared with insulin degludec in individuals starting a type 2 diabetes treatment with a second-generation basal insulin.
The new insulin glargine also reduces hypoglycemic events compared with other long-acting insulins, such as insulin glargine at 100 U / mL and insulin detemir, whether patients have started or changed their insulin therapy.
These findings, derived from a retrospective observational badysis of real-world data in the United States, were presented at the 78th Congress of the American Diabetes Association (ADA) which held in Orlando, Florida.
"Second-generation basal insulin is an effective and safe treatment option for people with type 2 diabetes because severe hypoglycaemia is a risk that affects many patients," said Jeremy Pettus, badistant professor of psychology. medicine. Real world comparative studies like LIGHTNING-PM can help people with type 2 diabetes and their physicians make informed decisions about treatment options. 19659003] The LIGHTNING study, as well as previous studies of the EDITION and DELIVER 2-7 programs, consistently demonstrate a significant reduction in the risk of hypoglycemia in patients on type 2 diabetes compared to other basal insulins first generation. The lower risk of hypoglycemia compared to insulin glargine 100 U / mL has been confirmed in several clinical trials.
Some studies also showed an insulin glargine profile 300U / mL more stable than insulin glargine 100 U / mL, and a flatter profile, with fewer daily fluctuations, insulin glargine 300U / mL compared with insulin
Pettus J et al., "Similar or less severe hypoglycemia rate with insulin glargine 300 U / ml (Gla-300) versus glargine 100 U / ml (Gla-100), Detemir (IDet) and Insulin Degludec (IDeg) in 112,626 people with type 2 diabetes mellitus (T2DM): predictive modeling using real data – lightning. Presentation 2289-PUB, 78th Annual Conference of the American Diabetes Association (ADA) June 24, 2018, Orlando, Florida, United States [19659007]
[ad_2]
Source link
